Results 11 to 20 of about 1,885,895 (335)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

Therapeutic Advances in Medical Oncology, 2020
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint ...
Laurence Albiges, Elie El Rassy, Ronan Flippot   +2 more
exaly   +2 more sources

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Cancers, 2020
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types ...
Nor Eddine Sounni, Charles Pottier, Guy Jerusalem   +2 more
exaly   +2 more sources

TYROSINE KINASE INHIBITORS AND INTERFERON

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj   +4 more sources

TYROSINE KINASE INHIBITORS AND PREGNANCY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti   +3 more
doaj   +4 more sources

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Biologics: Targets & Therapy, 2008
Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for ...
Sachin Gupta, Bassel F El-Rayes
doaj   +1 more source

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology, 2018
Introduction: We analyzed a large set of EGFR‐mutated (EGFR+) NSCLC to identify and characterize cases with co‐occurring kinase fusions as potential resistance mechanisms to EGFR tyrosine kinase inhibitors (TKIs).
Sai-Hong Ou, Samuel J Klempner, Russell Madison   +2 more
exaly   +2 more sources

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Haematologica, 2019
There are no validated molecular biomarkers to identify newly-diagnosed individuals with chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might benefit from first-line treatment with a more potent second-generation ...
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry, Richard Szydlo, Mary Alikian, Hui En Foong, Zacharoula Nikolakopoulou, Sandra Loaiza, Jamshid S. Khorashad, Dragana Milojkovic, Danilo Perrotti, Robert Peter Gale, Letizia Foroni, Jane F. Apperley   +15 more
doaj   +2 more sources

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Haematologica, 2015
This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Eolia Brissot, Myriam Labopin, Marielle M. Beckers, Gérard Socié, Alessandro Rambaldi, Liisa Volin, Jürgen Finke, Stig Lenhoff, Nicolaus Kröger, Gert J. Ossenkoppele, Charles F. Craddock, Ibrahim Yakoub-Agha, Günhan Gürman, Nigel H. Russell, Mahmoud Aljurf, Michael N. Potter, Armon Nagler, Oliver Ottmann, Jan J. Cornelissen, Jordi Esteve, Mohamad Mohty   +20 more
doaj   +2 more sources

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

Cancers, 2018
Tyrosine kinase inhibitors are a class of chemotherapeutic drugs that target specific protein kinases. These tyrosine kinase inhibitors constitute a relatively new class of drugs which target for instance Bcr-Abl, Epidermal Growth Factor Receptor (EGFR ...
Daniel J de Klerk, Richard J Honeywell, Godefridus J Peters   +2 more
exaly   +2 more sources

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +2 more sources